Mitochondrial cleavage inhibitor 1 (mdivi-1), an NLRP3 inflammasome inhibitor, has been proposed as a therapeutic agent for AD due to its ability to inhibit NLRP3 inflammasome activation and pyroptosis in keratinocytes under AD-like inflammation [48,49]. Here, NLRP3 is linked to Alzheimer disease.